Author:
McDonnell David P,Detke Holland C,Bergstrom Richard F,Kothare Prajakti,Johnson Jason,Stickelmeyer Mary,Sanchez-Felix Manuel V,Sorsaburu Sebastian,Mitchell Malcolm I
Publisher
Springer Science and Business Media LLC
Subject
Psychiatry and Mental health
Reference22 articles.
1. European Medicines Agency: Assessment report for Zypadhera. 2008, [
http://www.ema.europa.eu/humandocs/PDFs/EPAR/Zypadhera/H-890-en6.pdf
]
2. Detke HC, McDonnell DP, Brunner E, Zhao F, Sorsaburu S, Stefaniak VJ, Corya SA: Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases. BMC Psychiatry. 2010, 10: 43-10.1186/1471-244X-10-43.
3. Electronic Medicines Compendium: Summary of product characteristics for ZYPADHERA 210 mg, 300 mg, and 405 mg, powder and solvent for prolonged release suspension for injection. 2009, [
http://www.medicines.org.uk/emc/medicine/21361/SPC/ZYPADHERA
]
4. Shrewsbury R: Applied pharmaceutics in contemporary compounding. 2008, Englewood: Morton Publishing Company, 2
5. Kane JM, Detke HC, Naber D, Sethuraman G, Lin DY, Bergstrom RF, McDonnell DP: Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia. Am J Psychiatry. 2010, 167: 181-189. 10.1176/appi.ajp.2009.07081221.
Cited by
74 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献